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PRENATAL OPIOID MAINTENANCE IN THE U.S. AND ITS EFFECT ON 




Introduction: West Virginia’s opioid epidemic has been the cause of about 1,000 deaths each 
year.  Opioid abuse has become an issue among pregnant mothers and has increased the effects 
of NAS in infants.  The purpose of this research study was to evaluate the participation of 
prenatal opioid maintenance to determine if it has decreased the amount of treatment needed for 
NAS in infants in WV.   
 
Methodology:  The methodology for this study utilized a literature review and a semi-structured 
interview.  It consisted of academic sources, five electronic databases, academic journals, and 
government websites.  Thirty-seven sources were referenced for this literature review. 
 
Results: The literature review analyzed opioid maintenance therapy during pregnancy and its 
effect on the severity of NAS.  It was found that BMT had the most positive effect on NAS after 
birth. This review also reported a lack of availability for addicted pregnant women to enroll in 
maintenance programs and a high drop-out rate. 
 
Discussion/Conclusion: Opioid maintenance therapy has permitted pregnant women to refrain 
from illicit drug use without experiencing withdrawal symptoms and allowed the opportunity for 
their infants to have better health after birth. The study reviewed limitations that included the 
lack of treatment accessibility and had retractions due to difficulty distinguishing between 
generic drug names, databases used, and publication bias.  Practical implications included 
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continual participation of opioid addicted pregnant women and further research of new 
pharmaceuticals.  
 





The opioid epidemic in the United States (US) has led to 42,249 overdose deaths per year, and in 
West Virginia (WV) it was the cause of 52 per 100,000 deaths (CDC, 2017). In 2017, more than 
115 Americans died per day from opioid overdose: the CDC estimated a total of $78.5 billion per 
year has been consumed on healthcare due to loss of productivity, addiction treatment, and 
criminal justice related to opioid abuse (NIDA, 2018a). Excessive opioid abuse in the US has 
increased the occurrence of Neonatal Abstinence Syndrome (NAS) among infants, especially in 
WV (Santhanam, 2017).  
NAS occurs in infants who have been exposed to opioid usage by drug dependent 
mothers throughout pregnancy (Ko, et. al., 2016).  NAS has been defined as an opioid 
withdrawal syndrome that has been found in 55% to 94% of newborns whose mothers have used 
opioid drugs while pregnant (Nair, Soraisham, & Akierman, 2012).  It has been caused by the 
use of Heroin, Codeine, Oxycodone, Methadone, and Buprenorphine, which has led to health 
complications that have commenced within one to three days after birth (Medline Plus, 2017).  
The WV state average of children born with NAS was 7.74 per 1,000 births in 2007 and 
increased to 31.56 per 1,000 births by 2013, which was three times the national average (Stabler, 
et. al., 2017). 
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 Prenatal drug rehabilitation centers have used Methadone Maintenance Therapy (MMT) 
and Buprenorphine Maintenance Therapy (BMT) and has sustained opioid maintenance in 
addicted pregnant mothers (Forray, 2016).  The Maternal Addiction Recovery Center (MARC) 
Program in Huntington, WV at Marshall Obstetrics & Gynecology has offered the combination 
of prenatal care and medication maintenance to opioid-addicted pregnant women (Hendricks, 
2013).  Buprenorphine and Methadone have worked as opioid agonists and have contained 
chemicals that have linked to the brain’s opioid receptors and have reduced withdrawal 
symptoms from Heroine or other opioids, managed pain, and have created a sense of well-being 
(Reuter & Benckiser, 2013).  MMT and BMT during pregnancy has stabilized the amount of 
opioids within the fetus, decreased the risk of transmitting HIV to the fetus, and has improved 
overall neonatal health (NIDA, 2018b).  The use of Suboxone has also been implemented during 
pregnancy, which has consisted of the combination of Buprenorphine and Naloxone (American 
Addiction Centers, 2018).  Researchers conducted the Maternal Opioid Treatment: Human 
Experimental Research (MOTHER) project, which compared Buprenorphine and Methadone 
treatment among opioid addicted pregnant women, and concluded that Buprenorphine has been 
the most effective form of treatment for prenatal opioid dependence (Jones, et. al., 2012a).   
The purpose of this research study was to evaluate the participation of prenatal opioid 
maintenance to determine if it has decreased the amount of treatment needed for Neonatal 
Abstinence Syndrome in infants in West Virginia.   
METHODOLGY  
The primary hypothesis for this study was that opioid maintenance therapy among pregnant 
women has decreased the occurrence and severity of NAS in infants.  The methodology for this 
research analysis utilized a literature review of academic sources. The conceptual framework, 
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illustrated by Figure 1, showed an adaptation of the research framework by Brogly, Hahn, Diaz, 
& Werler, 2015, which demonstrated the benefits and barriers to opioid maintenance treatment 
during pregnancy. The use of this framework was appropriate because it demonstrated the 
adoption of MMT and BMT within prenatal drug treatment programs. It was similar to any 
project development in that the process was circular; it began with identification and definition 
of the opioid crisis and included development solutions. In this case, the solution has been 
preventing illicit drug usage or withdrawal during pregnancy through the use of maintenance 
medications to reduce NAS severity. Through process assessment, the use of opioid maintenance 
among pregnant women was researched, and the statistics showed positive effects on the infants 
after birth. Once prenatal drug treatment programs implemented the usage of medicated-
maintenance therapy, benefits and barriers were addressed (Figure 1).  
The literature review was conducted in three individual stages involving: (1) developing a search 
strategy and gathering data for the case study; (2) determining and analyzing the relevant 
literature; (3) delegating literature to appropriate categories.  
Step 1: Literature Identification and Collection  
The electronic databases used include JAMIA, Elibrary, PubMed, Medline, and Google Scholar. 
The terms searched within each database were: “prenatal drug programs” AND “opioid 
maintenance” OR “opioid therapy” AND “Neonatal Abstinence Syndrome” OR “NAS” OR 
“neonatal withdrawal syndrome” AND “WV” OR “US”.  Journals cited included: The Journal of 
the Medical Library Association, West Virginia Medical Journal, The Journal of Rural Health, 
Journal of Addiction Research & Therapy, and other reliable medical and government websites.  
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Step 2: Literature Analysis  
As the US and WV opioid crisis has continued to rise, it has become important to know its 
impact on pregnant women and their infants. Therefore, the literature analyzed focused on the 
following key areas: the utilization MMT and BMT, opioid maintenance completion, and 
severity of NAS after treatment has been administered. In attempt to collect the most recent data, 
sources preceding years 2008-2018 were removed from the search and only sources written in 
English were used. Primary and secondary data from articles, literature reviews, research studies, 
and reports written in the US were included in this research. The literature review included 37 
references which were assessed for information pertaining to this research project. Furthermore, 
a semi-structured interview with an expert Nurse Coordinator of prenatal opioid maintenance 
supplemented information to the data collected.  The Nurse Coordinator will be referred to as 
Expert in Prenatal Opioid Maintenance throughout the review.  The interview was tape recorded 
and IRB approval was obtained prior to execution. The literature search was conducted by MR 
and validated by AC, who acted as second reader and also double checked if references met the 
research study inclusion criteria.  
Step 3: Literature Categorization  
The following subheadings were included in part of the following research framework: Illicit 
Opioid Use During Pregnancy in the US and WV, Infants with NAS in the US and WV, MMT 
and BMT During Pregnancy, and Prenatal Opioid Maintenance Programs. 
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RESULTS 
Illicit Opioid Use During Pregnancy in the US and WV 
From 2008-2012, approximately 39.4% of female Medicaid patients and 27.7% of 
privately insured patients that were of childbearing age (15-44 years old) received opioid 
prescriptions each year (Krans & Patrick, 2016). These researchers also stated that out of more 
than 1 million Medicaid patients, 21.6% of pregnant women filled an opioid prescription and 
2.5% of prescriptions exceeded 30 days.  In 2011, 5% of women ages 15-44 years old in the US 
used illicit drugs while pregnant (Whiteman, et. al., 2014).  In addition, 138,224 out of 
55,781,965 hospitalizations among pregnant women were due to opioid abuse.  More than 35% 
of opioid dependent women have also tested positive for marijuana, cocaine, benzodiazepines, 
and 77%-95% and have smoked tobacco (Krans, Cochran, & Bogen, 2015).  
A study conducted in 2009 reported that 146 out of 759 pregnant women in WV, or 
19.2% tested positive for drug or alcohol abuse (Stitely, Calhoun, Maxwell, Nerhood, & Chaffin, 
2010).  In 2010, 1 out of 3 pregnant women positively tested for opioid abuse at Charleston Area 
Medical Center’s (CAMC) Women’s Medicine Center in Charleston, WV, but increased to 37% 
percent during the first quarter of 2011.  Furthermore, CAMC tested 706 pregnant mothers 
between July 2010 and July 2011, which showed usage of 74% marijuana, 20% opioid, 12% 
Benzodiazepines, and 6% Methadone (Harold, 2011).   
Infants with NAS in the US and WV 
Infants that have been born with NAS in the US more than doubled between years 2009 
and 2013, with an increased rate of 3.6 per 1,000 infants to a rate of 7.3 per 1,000 (Brown, 
Doshi, Pauly, & Talbert, 2016).  One study stated that in 2012, US hospitals expended $316 
million on infants with NAS, whose average length of stay was 16.6 days, or 3.5 times more than 
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a non-NAS infant (Corr & Hollenbeak, 2017).  Drug dependent infants in the US have had a 
150% greater chance of being readmitted into the hospital within 30 days after birth than infants 
born without any health complications (IDPH, 2017).  Medicated-maintenance has been utilized 
to treat withdrawal symptoms in 50%-70% of infants born with NAS (Krans, Cochran, & Bogen, 
2015). 
In 2016, the frequency of NAS among infants in WV was approximately 5% of total 
births (Holdren, 2017). This author also stated an increase from the two previous years, with 32.1 
per 1,000 infants born with NAS in 2014 and 34.4 per 1,000 in 2015.  Another report in 2017 
suggested that newborns with NAS were born every 25 minutes in WV (LeBeau, 2017).  In 
2013, 108 per 1,000 infants in Huntington, WV, were born with NAS, compared to the statewide 
amount of 37 per 1,000 and the nationwide rate of 7 per 1,000 (Davis, 2016). Four years later at 
Cabell Huntington Hospital in Huntington, WV, 140 per 1,000 infants were born with NAS, 
compared to the national average of 6 per 1,000 newborns (Lofton, 2017). 
According to WV perinatal collaborative officials, 33.3% of infants with NAS have been 
treated in well newborn nurseries, while the remaining 66.7% have been treated special care 
nurseries or the Neonatal Intensive Care Unit (NICU).  Furthermore, drug dependent infants 
have cost an average daily charge of $400 in WV’s neonatal withdrawal centers, $2,600 in a 
special care nursery, and $4,000 in a NICU (GAO, 2017).  A study conducted by West Virginia 
University suggested that the average length of stay for newborns with NAS was 18 days, which 
resulted in an overall hospitalization cost of $9,000-$12,600 (Towner, 2017).  Lily’s Place, an 
extended NAS treatment facility in Huntington, WV, has kept infants for 2 weeks to 12 months 
for addiction withdrawal treatment but only has 12 available beds: they have treated 91 infants 
since opening in 2014 (Davis, 2016). 
Morgan Ruley – Final Draft – April 30, 2018 – HCA 695 – Dr. Coustasse 
 8 
Methadone and Buprenorphine Maintenance Therapy During Pregnancy 
According to the MOTHER, infants whose mothers participated in MMT during 
pregnancy had a hospital stay extent of 15-20 days and NAS treatment duration of 10 days, 
whereas infants whose mothers used BMT had a hospital stay of 10 days and NAS treatment 
duration for less than 5 days (Whitten, 2012). Researchers have suggested that within 4 weeks of 
the being transitioned from MMT to BMT, 15% of women showed illegal drug usage in urine 
screening, 90% continued follow-up appointments until delivery of the child, and 38.9% did not 
use drugs illicitly at the time of delivery (Johnson & Martin, 2017).  Furthermore, there were 
fewer cases of NAS and shorter hospitals stays after birth when transitioned from MMT to BMT.  
 A recent study showed that BMT, rather than single-methadone treatments, has shown a 
10% lower chance of NAS, 8.4 fewer days of neonatal treatment, and 3.6 mg less Morphine 
treatment (NIDA, 2018c).  BMT has shown a longer duration of movements and less suppression 
in motor activity in infants (Jones, et. al., 2012b). Researchers from WVU reported that 81% of 
infants who have been exposed to MMT still needed treatment for NAS, while only 26% who 
were exposed to BMT required NAS treatment (Nanda, Brant, Regier, & Yossuck, 2015).  In a 
study that involved 716 women participating in MMT or BMT, infants whose mothers were 
exposed to MMT showed a 65% incidence of NAS, whereas those exposed to BMT showed 49% 
(Lemon, et. al., 2018). This study also showed 17 more cases of NAS when mothers participated 
in MMT rather than BMT. 
Prenatal Opioid Maintenance Programs  
 The MARC Program in Huntington, WV has the capacity to treat 36 patients, which have 
ranged from ages 22-34 years of age (Expert in Prenatal Opioid Maintenance, 2018).  However, 
upon the occasion that MARC has been unable to treat anymore patients, they have contacted an 
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alternate facility and placed them on their waiting list.  The Expert in Prenatal Opioid 
Maintenance stated that drug tests, which have included urine and blood screenings, have been 
performed weekly.  Furthermore, if drugs screenings were not clear, a breach in contract has 
occurred, and patients must discontinue treatment.  The Expert reported that Buprenorphine has 
been administered to MARC patients during the term of pregnancy at a maximum dose of 16 mg 
per day.  After delivery, however, patients have been prescribed Suboxone, which also has a 
maximum dose of 16 mg per day.  Each patient has been prescribed a different dose depending 
on each individual’s level of addiction and have experienced minimal side effects such as nausea 
or headaches (Expert in Prenatal Opioid Maintenance, 2018).  In addition to medication, the 
Expert also stated that patients have been required to attend group counseling, monthly 
individual meetings, and two Narcotics Anonymous meetings per month. The Expert reported 
that there have not been any cases of overdose while participating in the MARC Program.  
 One study in 2017 stated that only 16% of drug dependent pregnant women have 
successfully completed an opioid maintenance program and sustained from illicit drug use until 
the time of delivery (Klaman, et. al., 2017).  Researchers have found that the dropout rate of 
mothers who used Buprenorphine as maintenance medication was 33%, which was significantly 
higher than the 18% dropout rate of pregnant women who used Methadone during maintenance 
therapy (Stover & Davis, 2015). Between the years of 1992-2012, the number of pregnant 
women who were admitted into prenatal opioid therapy facilities due to prescription opioid drug 
usage increased from 2% to 28% (Krans & Patrick, 2016).  Finally, a study that consisted of 95 
women showed that 44% relapsed and resorted to illicit drug use before giving birth (Krans, 
Cochran, & Bogen, 2015). 
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DISCUSSION 
The purpose of this research study was to evaluate the participation of prenatal opioid 
maintenance to determine if it has decreased the amount of treatment needed for Neonatal 
Abstinence Syndrome in infants.  The primary hypothesis for this study was that opioid 
maintenance therapy among pregnant women has decreased the occurrence and severity of NAS 
in infants.  This analysis showed that prenatal opioid maintenance, especially with the use of 
Buprenorphine, has decreased the need for NAS treatment after birth and increased overall health 
in infants born to mothers who have participated in medication maintenance therapy. 
 One study showed that 5% of women within child bearing ages illicitly used opioids 
during their term of pregnancy (Whiteman, et. al., 2014).  In WV, the amount of opioid-addicted 
pregnant women has continued to increase each year: this has resulted in more than twice as 
many cases of NAS.  Hospitals have expended over $300 million to treat infants with NAS, 
which have required 3.5 longer hospital stays than healthy newborns due to medicated-
maintenance and health complications (Corr & Hollenbeak, 2017).  Holdren, 2017 suggested that 
NAS occurred in 5% of total births in WV in 2016, which has shown a continual increase each 
year.  Cabell Huntington Hospital in Huntington, WV, had 134 more cases of NAS  per 1,000 
newborns than the remainder of hospitals in the state. 
 Studies have shown that BMT throughout pregnancy has been more effective for NAS 
after delivery than MMT.  Johnson & Martin, 2017 reported less cases of NAS and a shorter 
length of stay with BMT. Furthermore, another study found that a significant amount of MMT 
exposed infants still needed treatment, compared to those who were exposed to BMT (Lemon, et. 
al., 2018).  The MARC Program in Huntington, WV has had a 100% completion rate using 
BMT, with minimal side effects.  After delivery, MARC patients have been prescribed Suboxone 
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for maintenance.  Patients have also attended counseling and meetings as supplementary forms 
of treatment (Expert in Prenatal Opioid Maintenance, 2018). On the contrary, Klaman, et. al., 
2017 reported only 16% of women have completed a program without returning to illicit drug 
use.  Furthermore, the need for prenatal opioid maintenance has continued to increase. Between 
1992-2012, the need for medication maintenance increased by 26% (Krans & Patrick, 2016).   
 A positive component of opioid maintenance therapy throughout the term of pregnancy in 
WV and the US has been the decrease in necessary treatment and severity of NAS in infants after 
birth. BMT has decreased the occurrence of NAS in infants to 49% and has decreased treatment 
needed for those born with NAS. 
 A negative component to prenatal opioid maintenance has been the dropout or relapse 
rate of pregnant mothers.  Prenatal opioid maintenance programs also have not had the capacity 
to treat every opioid-addicted pregnant mother that has been seeking medication maintenance 
therapy. 
Limitations  
 This research study was not conducted without its limitations.  Prenatal opioid 
maintenance programs have not had the capacity for all pregnant mothers who have needed 
treatment, which has resulted in NAS severity among infants.  This literature review was 
restricted due to search strategy such as difficulty distinguishing generic drug names, number of 
databases or sources found, which may have affected the availability or accuracy of the research, 
and finally research and publication bias.  Further research of Buprenorphine, Methadone, or 
new drugs is needed to ensure better results of NAS occurrence in the future. 
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Practical Implications 
 Continual participation in maintenance medication and cooperation of opioid-addicted 
pregnant women will help with further research regarding the occurrence and severity of NAS in 
newborns.  BMT has decreased the need for opioid treatment in infants after birth and improved 
their overall health.  The practical implications of prenatal opioid maintenance outcomes will 
need to be more heavily researched as more pregnant mothers continue to participate or drop-out 
of programs and new drugs come into the market. 
CONCLUSION 
Participation in opioid maintenance therapy during pregnancy has shown a decrease in severity 
of NAS infants.  This literature review has suggested that BMT has been the most effective form 
of treatment thus far. 
SEMI-STRUCTURED INTERVIEW 
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Questions Asked in Semi-Structured Interview of an Expert in Prenatal Opioid Maintenance on 
March 20, 2018 
• What is your rate of relapse? 
• How often have patients become opioid-free by the time of delivery? Why? 
• How frequently do you perform drug tests? 
• What is the range of ages currently enrolled? Why? 
• Does a certain age group have a higher completion rate? Why? 
• How many women can you have enrolled at once? 
• How many women do you have to turn away? Why? 
• What are the requirements/repercussions of staying in the program? 
• What maintenance medication do you use? Why? 
• How often is medication administered? Why? 
• If more than one form of treatment is used, have you found one to be more effective than 
the other? Why? 
• What are the side effects of medication used for treatment? 
• How many miscarriages have been reported? 
• Have any women overdosed while participating in your program? 
• If known, how has your program impacted the infants of your patients? Why? 
